09688 ZAI LAB
WatchlistZAI LAB News
Asian Equities Traded in the US as American Depositary Receipts Edge Higher in Wednesday Trading
Asian equities traded in the US as American depositary receipts edged higher Wednesday morning, with the S&P Asia 50 ADR Index advancing 0.08% to 1,670.22. From North Asia, the gainers were led by sol
Argenx Slips as Autoimmune Disorder Therapy Fails in Pivotal Trial
Financial Stocks Lead Asian Equities Traded in the US as American Depositary Receipts Higher in Friday Trading
Financial services stocks led Asian equities traded in the US as American depositary receipts modestly higher Friday morning, rising 0.28% to 1,659.95 on the S&P Asia 50 ADR Index. From North Asia, th
Zai Lab Limited (NASDAQ:ZLAB) Is Largely Controlled by Institutional Shareholders Who Own 79% of the Company
Key Insights Given the large stake in the stock by institutions, Zai Lab's stock price might be vulnerable to their trading decisions 53% of the business is held by the top 9 shareholders Analyst
Zai Lab Executive Purchases 5,000 Shares
Zai Lab Insider Bought Shares Worth $134,650, According to a Recent SEC Filing
Joshua L Smiley, President, and Chief Operating Officer, on November 16, 2023, executed a purchase for 5,000 shares in Zai Lab (ZLAB) for $134,650. Following the Form 4 filing with the SEC, Smiley has
Zai Lab(ZLAB.US) Officer Buys US$134.65K in Common Stocks
$Zai Lab(ZLAB.US)$ Officer Smiley Joshua L purchased 5,000 shares of Common Stocks on Nov 16, 2023 at an average price of $26.93 for a total value of $134.65K.Source: Announcement What is statement of
Zaiding Pharmaceutical (09688.HK) grants share options and restricted share units
Gelonghui November 16丨Zaiding Pharmaceutical (09688.HK) announced that on November 13, 2023 (EST), the company granted 2 undertakers the right to subscribe for a total of 13,500 American Depositary Shares and granted restricted share units involving a total of 54,000 American Depositary Shares to 4 underwriters and granted 4 undertakers restricted share units involving a total of 54,000 American Depositary Shares.
Zai Lab's Strong Sales Performance and Market Dominance Bolsters Buy Rating: An Analysis by David Li
Zaiding Pharmaceutical (09688.HK) received an increase in J.P. Morgan's holdings by 2,652,400 shares
Gelonghui November 13 | According to the latest equity disclosure data from the Stock Exchange, on November 6, 2023, Zaiding Pharmaceutical (09688.HK) received JPMorgan Chase & Co. to increase its position by 2,652,400 shares at an average price of HK$21.9865 per share, involving approximately HK$583.173 million. After increasing its holdings, the latest number of positions held by JPMorgan Chase & Co. was 120,744,604 shares, and the position ratio increased from 11.94% to 12.21%.
Analysts Are Bullish on These Technology Stocks: Zai Lab (ZLAB), Navitas Semiconductor (NVTS)
Tech Stocks Nudge Asian Equities Traded in the US as American Depositary Receipts Slightly Higher Thursday Morning
Tech stocks helped Asian equities traded in the US as American depositary receipts nudge slightly higher Thursday morning as they were rising 0.12% to 1,598.59 on the S&P Asia 50 ADR Index. From North
Telecoms Firms Lead Asian Equities Traded in the US as American Depositary Receipts Lower in Wednesday Trading
Asian equities traded in the US as American depositary receipts were trending lower Wednesday morning, led by telecoms stocks, as they were falling 0.85% to 1,602.82 on the S&P Asia 50 ADR Index. From
Analysts Conflicted on These Technology Names: AUTO1 Group SE (OtherATOGF), Rivian Automotive (RIVN) and Zai Lab (ZLAB)
Zai Lab's Q3 Loss Narrows, Revenue Increases
Zai Lab (ZLAB) reported a Q3 loss late Tuesday of $0.71 per diluted American depositary share, compared with a loss of $1.68 a year earlier. Four analysts polled by Capital IQ expected a loss of $0.98
Hong Kong stocks closed (11.08) | The Hang Seng Index closed down 0.58%, and domestic housing stocks soared at the end of the session, oil and non-ferrous metals stocks were under pressure throughout the day
Hong Kong's Hang Seng Index opened down 0.11%. The Hang Seng Index fluctuated and rebounded after opening low in early trading. It once rose nearly 80 points in the intraday period, then the increase narrowed somewhat, then declined at an accelerated pace in the afternoon.
Zaiding Pharmaceutical (09688.HK): Product revenue for the third quarter was US$69.2 million
On November 8, Gelonghui Pharmaceutical (09688.HK) announced that product revenue for the third quarter of 2023 was US$69.2 million, compared to US$57 million for the same period in 2022, up 22% year on year, and 27% year on year at fixed exchange rates. The increase in product revenue was mainly due to the increase in sales volume, the launch of Weijia, and the reduction in the negative impact of the COVID-19 pandemic. Wei Weijia (Agamod alpha injection) has achieved sales revenue of 4.9 million US dollars since it was commercialized and listed in China in September. Dr. Du Ying, founder, chairman and CEO of Zaiding Pharmaceutical said, “20
ZAI LAB: UNAUDITED RESULTS FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2023 AND CORPORATE UPDATES
Recap: Zai Lab Q3 Earnings
Zai Lab (NASDAQ:ZLAB) reported its Q3 earnings results on Tuesday, November 7, 2023 at 04:05 PM.Here's what investors need to know about the announcement.EarningsZai Lab beat estimated earnings by 25.
Zai Lab GAAP EPS of -$0.71 Beats by $0.27, Revenue of $69.23M Beats by $2.87M